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INTRODUCTION:  Associating  liver  partition  and  portal  vein  ligation  for  staged  hepatectomy  (ALPPS)  has
recently  been  developed  for  patients  with  predicted  insufﬁcient  future  liver  remnant  volumes  to induce
more  rapid  hepatic  hypertrophy  and  increase  resectability.  In the medical  literature,  the use of ALPPS in
hepatocellular  carcinoma  (HCC)  has rarely  been  reported.
PRESENTATION  OF  CASE:  We  reported  the use  of  ALPPS in  a patient  with  primarily  unresectable  HCC
arising  from  a background  of hepatitis  B related  liver  ﬁbrosis.  Preoperative  computed  tomography  (CT)
showed  2 large  conglomerated  tumors  measuring  16  cm  × 10.5  cm  in liver  segments  5, 6, 7  and  8, and  at
least  3 satellite  nodules  with  the  largest  one  measuring  3 cm  around  the  main  tumor  and  another  4 cm
tumor  in  segment  4.  Right  trisectionectomy  after  ALPPS  was successfully  performed.  He  was  discharged
from  hospital  on  postoperative  day  13  after  the second  operation.  Follow-up  CT scan  at 6  weeks after  the
second  operation  showed  further  hypertrophy  of  the  liver remnant  and no liver recurrence.
DISCUSSION:  Our  case  showed  that this  novel  strategy  is  feasible  even  in the  context  of a  background  of
chronic  hepatitis  B related  liver  ﬁbrosis,  although  the  hypertrophy  rate  was  a little  bit  slower  and  the
time  needed  was  longer.
CONCLUSION:  ALPPS  is also  feasible  in  liver ﬁbrosis.  It  gives  hope  to  patients  with  HCC who  previously  were
considered  as having  unresectable  diseases.  More  studies  are  needed  to further  evaluate  the  effectiveness
and  oncological  outcomes  of ALPPS  from  these  patients.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Trisectionectomy has been associated with higher complication
ates and increased postoperative liver dysfunction/failure than
iver resections involving lesser volumes. Preoperative portal vein
mbolization (PPVE) and portal vein ligation (PVL) have been used
o induce hepatic hypertrophy of future liver remnant and to reduce
he risk of post-hepatectomy liver failure in patients who have
nsufﬁcient future liver remnants.1,2 To induce more rapid hepatic
ypertrophy and to increase resectability, associating liver parti-
ion and portal vein ligation for staged hepatectomy (ALPPS) has
ecently been developed. This technique was ﬁrst carried out by
r. Hans Schlitt from Regensburg in 2007 and it was ﬁrst pre-
ented in a German Congress in 2010.3 The procedure requires
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liver parenchymal transection just to the right of the umbilical ﬁs-
sure with simultaneous right portal vein ligation during the ﬁrst
stage of the operation, followed about one to two weeks later by
completion right trisectionectomy. The novelty of ALPPS is the
marked percentage gain of patients to resectability. To the best
of our knowledge, no prospective studies comparing traditional
methods (PPVE, PVL or two staged hepatectomy strategy) with
ALPPS are now available. The retrospective study of Schadde et al.
showed the extrapolated growth rate in ALPPS was 11 times higher
(34.8 ml/day) than PPVE/PVL (3 ml/day).4 Despite the sudden
increase in reports on ALPPS during the last 2 years, a lot of ques-
tions concerning the safety and effectiveness of ALPPS remained
unanswered. Currently, ALPPS is still considered to be in an early
development phase, and its indications and techniques are not
standardized.
In the literature, the use of ALPPS in hepatocellular carcinoma
(HCC) has rarely been reported. The majority of reports were on
colorectal liver metastases and hilar cholangiocarcinoma arising in
normal livers. We  reported the use of ALPPS in a patient with a large
HCC with hepatitis B related liver ﬁbrosis.
s Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. (a) Right portal vein ligation in ﬁrst stage of operation. (b) Liver parenchymal transection for right trisectionectomy (segments 4–8) at the right side of the falciform
ligament. (c) Operative view after the ﬁrst stage of operation.
Fig. 2. (a) Operative view during the second stage of operation. (b) Signiﬁcant hypertrophy of segments 2 and 3 in the second stage of operation. (c) Post completion right
trisectionectomy in the second stage of operation.
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wig. 3. (a) CT scan with volumetry before the ﬁrst stage of operation. (b) CT scan wit
efore  the ﬁrst stage of operation.
. Presentation of case
A 55-year-old male presented with epigastric discomfort and
ecent weight loss of 4.5 kg. He had a history of hepatitis B
elated cirrhosis and a history of splenectomy for traumatic
njury many years ago. His contrast enhanced computed tomogra-
hy (CT) showed 2 large conglomerated tumors, one measuring
6 cm × 10.5 cm in segments 5, 6, 7 and 8, and another 4 cm in
egment 4. There were at least 3 satellite nodules around the
ain tumor, with the largest one measuring 3 cm.  His liver func-
ion showed bilirubin, 7 mol/L; albumin, 31 g/L; prothrombin
ime, 13.5-s; creatinine, 77 mol/L; hemoglobin, 14.1 g/dL; platelet
ount, 435 × 109 L−1. Indocyanine green retention rate at 15 min
ICG-R15) was 9.3%. Alpha-fetoprotein (AFP) level was 3044 ng/ml.
ntecavir (Baraclude) was started before the operation.
.1. Procedure: upper midline incision was used in the ﬁrst
peration
At the ﬁrst operation only the round ligament and the falci-
orm ligament were divided and both sides of the liver were not
obilized. A thorough exploration and intraoperative ultrasound
IOUS) were used to assess and stage the liver tumors. Cholecys-
ectomy was performed before the right hilar dissection. The right
ortal vein was ligated with strong silk tie and was not divided.
he right hepatic artery and the right hepatic duct were identiﬁed,
ere not isolated separately, and marked with vessel loops. Livereconstruction before the ﬁrst stage of operation. (c) CT scan with 3D reconstruction
parenchymal transection was  carried out on the right side of the
falciform ligament using a CUSA (Cavitron Ultrasonic Surgical Aspi-
rator). The segment 4 pedicles were transected with endostaplers. A
leak test was  performed via the cystic duct and it conﬁrmed no bile
leakage in the liver transection plane. No wrapping/interposition
material at the transection surface was  used. A silicone drain was
inserted near the transection surface (Fig. 1a–c).
After CT scan with volumetric assessment, the second phase
of the operation was performed 14 days after the ﬁrst operation.
In the second operation, a right transverse abdominal incision
was added in addition to the midline incision in the ﬁrst oper-
ation. The right liver was  then mobilized from the inferior vena
cava (IVC), and all the retrohepatic veins draining the right liver
were ligated and divided. The right hepatic duct, right portal vein,
right hepatic artery, right hepatic vein and middle hepatic vein
were divided with endostaplers and the tumor-bearing liver was
removed with a 11.5 cm × 6 cm patch of diaphragm. The diaphragm
was repaired directly without any mesh. A 16Fr chest drain was
inserted (Fig. 2a–c). No Pringle maneuver was needed during these
two operations.
2.2. Volumetric assessmentCT scan with volumetry assessment was performed before the
ﬁrst operation and at completion of surgery. 3-Dimensional (3D)
CT scan reconstruction was  also performed using Yortal 3D recon-
struction system (Yortal Digital Medical Imaging Tech Co. Ltd.,
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the most common complications. Another major question whichig. 4. (a) CT scan with volumetry at 8 days after the ﬁrst stage of operation. (b) CT
D  reconstruction at 8 days after the ﬁrst stage of operation.
hina). The preoperative remnant liver volume to total liver vol-
me  ratio (RLV/TLV) ratio was 26.9%. After 8 days, the RLV/TLV ratio
ncreased to 37.4%. The FLV (segments 2, 3 and part of segment 1)
ncreased from 383 ml  to 532 ml  (Figs. 3a–c and 4a–c).
.3. Operative parameters and post-operative course
At the ﬁrst operation, the operating time was  231 min, and
lood loss was 500 ml.  At the second operation, the operating time
as 198 min, and blood loss was 700 ml.  No perioperative blood
ransfusion was needed. The patient resumed oral diet intake on
ost-operative day 2 after the ﬁrst and the second operations. He
ad a transient increase in drain output of ascitic ﬂuid after the sec-
nd operation, which subsided with medical treatment. His liver
unction recovered gradually and he had no bile leak. The patient
as discharged home on postoperative day 13 after the second
peration.
.4. Histopathology
Histopathology conﬁrmed a 16.5 cm × 10.5 cm × 18 cm HCC in
he right liver and a 3.2 cm HCC in segment 4, with Edmondson
 Steiner grade 3 and pT3a. These were extensive tumor necro-
is and presence of microscopic vascular invasion but no deﬁnite
ortal vein tumor thrombus. The resection margins were clear. The
iver parenchyma showed chronic hepatitis changes with bridging
brosis.with 3D reconstruction at 8 days after the ﬁrst stage of operation. (c) CT scan with
2.5. Follow-up
Follow-up CT scan at 6 weeks after the second operation showed
further hypertrophy of the liver remnant. There was no recurrence
(Fig. 5). He remained well at 2 months after the ALPPS. The AFP level
at 6 weeks after operation was  6 ng/ml.
3. Discussion
ALPPS has been adopted all over the world in the past 2 years,
even though the oncological long-term results remain unknown,
and beneﬁt for patients is still questionable. Even if the onco-
logic outcomes are acceptable, it remains controversial whether the
gain in quality of life and survival could balance the high risks of
complication and mortality. The current evidence suggested that
ALPPS offered a better chance of complete resection in patients
who had primarily unresectable liver tumors at the cost of high
operation morbidity and mortality. The morbidity rate has been
reported to be as high as 70%, with high rates of procedure-related
deaths of about 15%.4–9 Bile leakage from the raw surface of the
liver and septic events secondary to ischemic necrosis of liver wereremained unanswered is whether stimulation of liver hypertrophy
could also accelerate tumor progression. This is a question which
has been debated since the time of PPVE/PVL techniques. Many
reports showed accelerated tumor growth after PPVE is of major
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cFig. 5. Follow-up CT scan at 6 weeks after the 2nd operation show
oncern and requires consideration of post-PVE chemotherapy.10,11
hus, ALPPS also has a potential to promote tumor recurrence
nd progression. Recently, Oldhafer et al. reported that for the 10
atients with unresectable colorectal liver metastases who  under-
ent ALPPS, 6 of the 7 patients who had a follow-up of at least
 months developed tumor recurrence in the liver. In addition, 3
f the 7 patients developed lung metastases, which appeared ear-
ier than the liver metastases in 2 of the 3 patients. The remaining
atient with a follow-up of 3 months had no radiological recur-
ent disease, but had increasing carcinoembryonic antigen (CEA)
evels.12 Whether the rapid hypertrophy itself promotes tumor
ecurrence remains uncertain and this requires further investiga-
ion.
Several series in the medical literature described a median of
4–110% increase in FRL volume at a median of 9–15 days between
he 2 steps of the operation.4–9 These livers were mainly normal
iver. Our case showed that this novel strategy was feasible even
ith a chronic hepatitis B related liver ﬁbrosis, although the hyper-
rophy rate was slower and the time frame needed for the 2 stages
f operation was longer.
In conclusion, ALPPS is also feasible in hepatitis B related liver
brosis. It gives a hope of cure for patients with unresectable dis-
ase. More studies are needed to further evaluate its effectiveness
nd oncological outcomes.
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